Pfizer Built a Three-Headed Monster to Dethrone Dupixent
Pfizer's first-in-class trispecific antibody tilrekimig just posted Phase 2 results that rival Dupixent in atopic dermatitis, hitting all three moles at once by blocking IL-4, IL-13, and TSLP simultaneously. With Phase 3 planned for 2026 and expansion into asthma and COPD on the horizon, the $15 billion blockbuster might finally have real competition.
Imagine you're playing whack-a-mole, but three moles pop up at once. You can only hit one at a time. That's roughly the problem with treating atopic dermatitis (severe eczema that affects over 200 million people worldwide). The disease is driven by multiple inflammatory signals, and most drugs only block one or two of them.
Pfizer just unveiled a mallet that hits all three moles simultaneously. And the early results suggest it works about as well as the reigning king of eczema treatment.
The $15 Billion Target on Dupixent's Back
To understand why this matters, you need to know one name: Dupixent.
Sanofi and Regeneron's blockbuster drug pulled in €13.1 billion (approximately $14.2 billion) in global sales in 2024, with roughly 73% of that revenue coming from atopic dermatitis alone. It works by blocking a receptor called IL-4Rα, which shuts down two key inflammatory proteins: IL-4 and IL-13. That approach was revolutionary when it launched. It changed millions of patients' lives.
But Dupixent doesn't touch everything fueling the fire. Think of it like locking the front door of a burning building while the back door stays wide open. Specifically, it leaves a protein called TSLP (thymic stromal lymphopoietin) completely unchecked. TSLP is the "master switch" that sits upstream of the whole inflammatory cascade; it's the protein that tells your immune system to start overreacting in the first place.
Pfizer's bet: what if you could block TSLP and IL-4 and IL-13 with a single drug?
One Antibody, Three Targets, Zero Precedent
The drug is called tilrekimig (try saying that three times fast), and it's a trispecific antibody. Most antibodies are like guided missiles with one target. A bispecific antibody can hit two. Tilrekimig hits three.
This is genuinely novel engineering. Building a single molecule that can grab onto three different proteins and neutralize all of them is like designing a Swiss Army knife that's actually good at all its functions, not just the main blade. Nobody has done this before in a clinical setting for eczema.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The idea is elegant: TSLP blockade cuts off inflammation at the source (the epithelial cells lining your skin), while IL-4 and IL-13 blockade mops up the downstream mess (the itching, redness, and skin thickening that make patients miserable). You're attacking the problem from both ends of the pipeline.
The Numbers That Caught Everyone's Attention
Pfizer tested tilrekimig in a Phase 2 trial of 269 adults with moderate to severe atopic dermatitis. The study used multiple stages, and Stage 2 tested three dose levels (low, middle, high) given monthly against placebo over 16 weeks.
The main measure was EASI-75, which means at least a 75% improvement in eczema severity. It's the standard yardstick in dermatology trials, and clearing that bar means patients experience dramatic, visible improvements in their skin.
All three doses beat placebo with statistical significance. But the middle dose stole the show: 51.9% of patients hit EASI-75 (placebo-adjusted, meaning that's after subtracting the placebo response). The high dose wasn't far behind at 49.4%, while the low dose came in at 38.7%.
Why is that noteworthy? Because those numbers are in the same neighborhood as Dupixent's Phase 2 performance. For a first-in-class drug with a completely new mechanism, matching the standard of care on your first real swing is a very promising sign.
The Safety Story Is Quietly Impressive
Efficacy is only half the equation. A drug that works beautifully but makes patients feel terrible is a drug that collects dust on pharmacy shelves.
Tilrekimig looked clean. Adverse event rates were comparable to placebo across all doses, with no dose-dependent safety signals. The most common side effects were the usual suspects: mild infections, skin reactions at the injection site, and general discomfort. Only three serious adverse events occurred in the trial, and none were related to treatment.
One detail worth highlighting: conjunctivitis (eye inflammation) was less frequent than what's typically seen with drugs that block IL-4Rα, like Dupixent. Eye problems have been a nagging issue for Dupixent patients, so if tilrekimig can deliver similar efficacy with fewer eye-related side effects, that's a meaningful clinical differentiator.
Why Three Is Greater Than Two (Maybe)
Skeptics will ask a fair question: does blocking TSLP on top of IL-4 and IL-13 actually add anything meaningful? After all, Dupixent already blocks the downstream culprits.
The biological rationale is solid. TSLP doesn't just trigger IL-4 and IL-13 production; it activates multiple inflammatory pathways (JAK-STAT, PI3K-AKT, NF-κB, if you want the alphabet soup) that contribute to Th2 inflammation through routes that IL-4/IL-13 blockade alone can't fully address. Blocking only the downstream cytokines is like arresting the getaway driver while the mastermind keeps planning new heists.
There's also a precedent for TSLP's importance. Tezepelumab, an anti-TSLP antibody from AstraZeneca, is already approved for severe asthma and has shown benefit across both type 2 and non-type 2 inflammatory phenotypes. That broad activity hints at TSLP's central role in driving inflammation.
The real proof, of course, will come in Phase 3. Phase 2 data is like a first date that went really well: encouraging, but you don't know if it'll last.
The Bigger Picture: Asthma and COPD
Pfizer isn't thinking small. Mike Vincent, Senior Vice President and Chief Scientific Officer of Pfizer's Inflammation and Immunology Research Unit, said the results "show that combining the potent inhibition of IL-4/13 and TSLP pathways has the potential to deliver improved efficacy over the standard of care for atopic dermatitis."
But atopic dermatitis might just be the opening act. Pfizer has signaled interest in expanding tilrekimig into asthma and COPD, two massive respiratory markets where the same Th2 inflammatory pathways drive disease. A once-monthly injection (the dosing schedule used in this trial) that tackles multiple conditions with one molecule would be incredibly attractive to patients and payers alike.
Layer on asthma and COPD, and tilrekimig could become the foundation of a multi-billion-dollar franchise, if the Phase 3 data holds up.
A Crowded Dance Floor
Pfizer isn't the only company trying to dethrone Dupixent. The atopic dermatitis competitive landscape is getting crowded.
AbbVie's Rinvoq (upadacitinib), a JAK inhibitor taken as a daily pill, is the fastest-growing segment in the market. JAK inhibitors tend to show high efficacy rates in trials, though they carry more safety baggage (think boxed warnings about cardiovascular risk and malignancies) that makes some doctors hesitant.
Then there's a wave of pipeline biologics targeting entirely different mechanisms. Amgen and Kyowa Kirin are developing rocatinlimab, Sanofi has amlitelimab targeting OX40-ligand (OX40L), and Astria Therapeutics has telazrolimab, all going after T-cell activation through OX40 pathway inhibition. Even Pfizer itself has another card to play: ompekimig, a separate multispecific antibody targeting IL-4, IL-13, and IL-33 (instead of TSLP), which also showed positive Phase 2 results.
Having two shots on goal in the same disease with different trispecific designs is a smart hedging strategy. It also tells you something about how seriously Pfizer is taking this market.
What Comes Next
Pfizer plans to kick off Phase 3 trials in 2026, with detailed results from the Phase 2 study expected at a future medical conference. The company has been on a pipeline offensive, with up to eight late-stage readouts anticipated across its portfolio.
For now, tilrekimig sits at an inflection point. The Phase 2 data is genuinely encouraging: Dupixent-rivaling efficacy, a clean safety profile, once-monthly dosing, and a mechanistic rationale that extends well beyond eczema. But Phase 2 trials are small, and plenty of drugs that looked great in 269 patients have stumbled when tested in thousands.
The question isn't whether Pfizer's three-headed antibody can compete with Dupixent. The Phase 2 data suggests it can. The question is whether it can do something Dupixent can't: block inflammation so comprehensively that patients achieve better outcomes, across more diseases, with fewer side effects.
If it pulls that off, Sanofi and Regeneron should be worried. And the 200 million people worldwide living with severe eczema should be hopeful.
Deals & M&A
4 min read
Novartis Just Paid $2 Billion for a Drug That Doesn't Have Data Yet
Novartis dropped $2 billion upfront on a breast cancer drug that won't have clinical data until 2027. With Eli Lilly's competing asset already in Phase 3, the deal is either a masterstroke of early positioning or one of the most expensive gambles in oncology M&A.
